Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8-10, 2025.
The company will conduct investor meetings on September 9, followed by a fireside chat featuring Dr. Balaji Prasad, Chief Strategy Officer, on September 10 at 10:45 am EDT. The fireside chat will be publicly accessible via webcast on Alvotech's investor relations website, with a 90-day replay period available after the event.
Alvotech (NASDAQ: ALVO), azienda biotecnologica globale specializzata nello sviluppo di medicinali biosimilari, parteciper脿 alla Morgan Stanley 23rd Annual Global Healthcare Conference a New York dall'8 al 10 settembre 2025.
La societ脿 terr脿 incontri con investitori il 9 settembre, seguiti da un fireside chat con il Dr. Balaji Prasad, Chief Strategy Officer, il 10 settembre alle 10:45 EDT. Il fireside chat sar脿 accessibile al pubblico tramite webcast sul sito investor relations di Alvotech e rester脿 disponibile in replay per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), compa帽铆a biotecnol贸gica global dedicada al desarrollo de medicamentos biosimilares, participar谩 en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York del 8 al 10 de septiembre de 2025.
La empresa ofrecer谩 reuniones con inversores el 9 de septiembre, seguidas de un fireside chat con el Dr. Balaji Prasad, Chief Strategy Officer, el 10 de septiembre a las 10:45 EDT. El fireside chat se podr谩 ver p煤blicamente por webcast en la web de relaciones con inversores de Alvotech y estar谩 disponible en reproducci贸n durante 90 d铆as tras el evento.
Alvotech (NASDAQ: ALVO))電� 氚旍澊鞓れ嫓氚�霟� 鞚橃暯頀� 臧滊皽鞐� 欤茧牓頃橂姅 旮�搿滊矊 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 9鞗� 8鞚茧秬韯� 10鞚缄箤歆� 雺挫殨鞐愳劀 鞐措Μ電� Morgan Stanley 23rd Annual Global Healthcare Conference鞐� 彀戈皜頃╇媹雼�.
须岇偓电� 9鞗� 9鞚�鞐� 韴瀽鞛� 氙疙寘鞚� 歆勴枆頃橂┌, 鞚挫柎靹� Chief Strategy Officer鞚� Dr. Balaji Prasad臧� 彀胳棳頃橂姅 韺岇澊鞏挫偓鞚措摐 毂勴寘鞚� 9鞗� 10鞚� 鞓れ爠 10:45(EDT)鞐� 鞐措雼堧嫟. 鞚� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞚� Alvotech 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暅 鞗轨簮鞀ろ姼搿� 瓿店皽霅橂┌, 頄夓偓 頉� 90鞚缄皠 鞛嫓觳澊 臧�電ロ暕雼堧嫟.
Alvotech (NASDAQ: ALVO), soci茅t茅 biotechnologique mondiale sp茅cialis茅e dans le d茅veloppement de m茅dicaments biosimilaires, participera 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference 脿 New York du 8 au 10 septembre 2025.
La soci茅t茅 tiendra des r茅unions avec des investisseurs le 9 septembre, suivies d'un fireside chat avec le Dr. Balaji Prasad, Chief Strategy Officer, le 10 septembre 脿 10h45 EDT. Le fireside chat sera accessible au public via un webcast sur le site relations investisseurs d'Alvotech et restera disponible en replay pendant 90 jours apr猫s l'茅v茅nement.
Alvotech (NASDAQ: ALVO), ein globales Biotech-Unternehmen, das sich auf die Entwicklung von Biosimilars spezialisiert hat, wird an der Morgan Stanley 23rd Annual Global Healthcare Conference in New York vom 8. bis 10. September 2025 teilnehmen.
Das Unternehmen f眉hrt am 9. September Investorengespr盲che durch, gefolgt von einem Fireside-Chat mit Dr. Balaji Prasad, Chief Strategy Officer, am 10. September um 10:45 Uhr EDT. Der Fireside-Chat wird 枚ffentlich per Webcast auf der Investor-Relations-Website von Alvotech verf眉gbar sein und kann 90 Tage nach der Veranstaltung nachgesehen werden.
- None.
- None.
REYKJAVIK, Iceland,聽June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference, which will be held in New York, NY, September 8-10, 2025. Alvotech will be meeting with investors on Tuesday, September 9, 2025, and Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday September 10, 2025, at 10:45 am EDT (14:45 GMT / 16:45 CET).
A live webcast of the fireside chat will be available to the general public and can be accessed at . After the event, a recording will be available for replay for 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech鈥檚 commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy鈥檚 (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our , and our or follow us on social media on , , , and .
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
[email protected]
FAQ
When is Alvotech (NASDAQ: ALVO) presenting at the Morgan Stanley Healthcare Conference 2025?
Who will represent Alvotech at the Morgan Stanley Healthcare Conference 2025?
How can investors access Alvotech's presentation at the Morgan Stanley Conference?
What activities will Alvotech participate in at the Morgan Stanley Healthcare Conference?
